Overview

An Open Label Study of L059 Intravenous (IV) in Japanese Epilepsy Subjects With Partial Onset Seizures

Status:
Completed
Trial end date:
2012-02-01
Target enrollment:
Participant gender:
Summary
To evaluate the safety of Levetiracetam IV 15-minute infusion administered every 12 hours as adjunctive treatment in subjects with Partial Onset Seizures after switching from the equivalent Levetiracetam oral dose.
Phase:
Phase 2
Details
Lead Sponsor:
UCB Japan Co. Ltd.
Treatments:
Etiracetam
Levetiracetam
Piracetam